Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cells + anti-thymocyte globulin
- Development stage
- Unknown
- Lead developer
- Chinese Academy of Medical Sciences
- Modality
- Cell Therapies, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy consists of umbilical cord-derived mesenchymal stem cells (UC-MSCs) and anti-thymocyte globulin (ATG). UC-MSCs are multipotent stromal cells known for their immunomodulatory and regenerative properties, which are thought to help repair and support the bone marrow microenvironment. ATG is a potent immunosuppressive agent that works by depleting T-lymphocytes, which are primarily responsible for the autoimmune destruction of hematopoietic stem cells in aplastic anemia. The combination is specifically being evaluated by the Chinese Academy of Medical Sciences for the treatment of children with severe aplastic anemia (SAA) to improve early response rates and long-term therapeutic outcomes compared to standard ATG treatment alone.
- Brand names
- Thymoglobuline
- Other names
- UC-MSC + ATGUmbilical Cord Derived Mesenchymal Stem Cells + ATGMSC and ATG
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cells + anti-thymocyte globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells + anti-thymocyte globulin.